HIGHLIGHTS
- who: Naohiko Kinoshita et al. from the nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Daigakumachi, Takatsuki City, Osaka, Japan have published the research work: Serum IL-13 Predicts Response to Golimumab in Bio-Nau00efve Ulcerative Colitis, in the Journal: (JOURNAL)
- what: This study aimed to evaluate whether serum biomarkers that were reported to be associated with UC or anti-TNF-u03b1 antibody could predict the to golimumab a human anti-TNF-u03b1 monoclonal antibody in bio-nau00efve patients with UC. This study focused on bio-nau00efve UC, which reduces diversity in the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.